Clinical Trials Logo

Clinical Trial Summary

1. Determine the maximum tolerable dose (MTD) and / or phase II recommended dose (RP2D) of the allotinib combined mXELIRI protocol. 2. To evaluate the safety and tolerance of the combination of anlotinib and mXELIRI in the second-line treatment of patients with advanced colorectal cancer

Clinical Trial Description

This study consists of two phases, the dose-escalation phase, and the expansion phase. 9-12 patients with advanced colorectal cancer will be included in the dose escalation study. Patients who met the inclusion criteria would be treated with anlotinib QD for 2 weeks, and then stopped for 1 week, combined with mXELIRI. Every 21 days was a treatment cycle. Safety information was collected until the disease progression or intolerable toxicity, so as to determine the MTD and / or RP2D of anlotinib combined with irinotecan in patients with advanced colorectal cancer. The study adopted the traditional 3+3 design . The primary outcome in dose-expansion phase was objective response rate(ORR). ;

Study Design

Related Conditions & MeSH terms

NCT number NCT05035914
Study type Interventional
Source Guangzhou University of Traditional Chinese Medicine
Contact Haibo Zhang, Professor
Phone 86 20 81887233
Email [email protected]
Status Recruiting
Phase Phase 1/Phase 2
Start date July 9, 2021
Completion date December 31, 2024

See also
  Status Clinical Trial Phase
Not yet recruiting NCT05028933 - IMC001 for Clinical Research on Advanced Digestive System Malignancies Phase 1
Not yet recruiting NCT02923622 - Efficacy and Safety Evaluation of Traditional Chinese Medicine in the Treatment of Advanced Colorectal Cancer N/A
Active, not recruiting NCT01723969 - Screening Platform for Clinical Trials in Advanced Colorectal Cancer
Active, not recruiting NCT00309179 - A Phase II Study of the Safety and Efficacy of E7820 Plus Cetuximab in Colorectal Cancer, Preceded by a Run-in Study in Advanced Solid Tumors Phase 2
Recruiting NCT03699111 - Identification of New Patient Stratification Tools in MSS RAS mt mCRC
Recruiting NCT04324476 - A Study of Bevacizumab Plus XELOX/XELIRI for First-line Treatment in Unresectable Advanced Colorectal Cancer Phase 2
Completed NCT00707889 - Phase 2 Study of ABT-869 in Combination With mFOLFOX6 Versus Bevacizumab in Combination With mFOLFOX6 to Treat Advanced Colorectal Cancer Phase 2
Terminated NCT01271166 - Glivec® Plus m-FOLFOX Avastin® in Advanced Colorectal Cancer Phase 1
Completed NCT00386828 - Chemoradiation for Locally Advanced and Low Rectal Cancers: Avastin-Capecitabine-Oxaliplatin-Radiation REctal Cancer Trial Phase 2
Not yet recruiting NCT04764006 - Surufatinib Combined With Sintilimab for Advanced MSS-Type Colorectal Cancer : a Phase II Study Phase 2
Recruiting NCT04835324 - Regorafenib Treatment Patterns and Survival Outcomes in Advanced Colorectal Cancer: A Real-world Study
Active, not recruiting NCT02619435 - Regorafenib Monotherapy as Second-line Treatment of Patients With RAS-mutant Advanced Colorectal Cancer Phase 2
Completed NCT01822444 - ANGIOPREDICT. ICORG 12-16, V3
Completed NCT00498407 - A Phase II Study of CP-4055 as Second Line Therapy in Patients With Advanced Colorectal Cancer Phase 2
Recruiting NCT04744831 - Trastuzumab Deruxtecan in Participants With HER2-overexpressing Advanced or Metastatic Colorectal Cancer Phase 2
Terminated NCT03311750 - Anti-EGFR Therapy Rechallenge in Combination With Chemotherapy in Patients With Advanced Colorectal Cancer Phase 2
Not yet recruiting NCT04734249 - Second-line Surufatinib Combined With Chemotherapy in Advanced CRC Phase 2
Completed NCT00637091 - Efficacy Analysis of Cetuximab Plus Irinotecan in Patients With Wild-type KRAS Without Regard to Epidermal Growth Factor Receptor (EGFR) Expressions Phase 2
Recruiting NCT04793958 - Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10) Phase 3
Completed NCT01859858 - Effect of Curcumin on Dose Limiting Toxicity and Pharmacokinetics of Irinotecan in Patients With Solid Tumors Phase 1